THAILAND · IVD

Thailand IVD combination panels and model variants: when to split applications

When preparing a Thai IVD registration, the number of analytes, the number of catalogue numbers to be sold and the number of applications are three different figures. One test platform can give rise to several separately sold combination panels, and one application can cover several items if they meet the grouping conditions. The starting point is the full intended use and configuration of each catalogue number to be sold, not the platform or the heading in the product catalogue.

Thai FDA’s IVD registration checklists, revised in May 2026, require the application form to state the grouping, risk classification and user group, and require documents and data for every item when one application covers more than one. (Source: Thai FDA IVD Full-CSDT checklist, pp. 1–3) For definitions of each grouping type, see MediPass’s Thailand medical device registration service; this article deals only with the specific decisions raised by combination panels, removed panel targets and professional versus self-test versions.

Count analytes, sales units and applications separately

A test cassette, buffer and collection swab in one box usually make up a single product for sale; four combination panels in the same manufacturer’s catalogue may be four separately sold products. Putting the latter into one application requires showing that they meet every condition of a grouping type, not merely that they share a brand, housing or platform.

The checklist requires the item list (Items) to state, for each item, the product name (matching the label), the foreign manufacturer and site, and the identifier on the label (REF, model or product code), and recommends giving the pack size in the additional description. (Source: Full-CSDT checklist, p. 2, Items rows 1–6) So before discussing grouping, build a model matrix by catalogue number. We suggest at least these columns:

  • Catalogue number and product name (as on the label)
  • Targets and their combination, test method and read-out
  • Specimen types and collection method
  • Users (professional/self-test), intended use and result interpretation
  • Kit components and pack size
  • Thai risk class and its basis
  • Configurations actually covered by existing performance studies

The matrix is a project tool suggested by MediPass, not an official form. Its purpose is to link each difference between models to the grouping condition and evidence that need checking.

Four ways to combine products: what does each have to answer?

The checklists refer to Thai FDA’s Medical Device Grouping Criteria (หลักเกณฑ์ในการจัดกลุ่มเครื่องมือแพทย์ พ.ศ. 2561) (announced 26 October 2018) for the detailed conditions. (Sources: Full-CSDT checklist and Abridged checklist, Items rows 4 and 5) The criteria set out six forms: Single, System, Family, Set, IVD Test Kit and IVD Cluster. Family conditions are in section 5.3, IVD Test Kit in section 5.5 and IVD Cluster in section 5.6; permissible variants are in Annex 3 and IVD Cluster categories in Annex 7. (Source: Thai FDA Medical Device Grouping Criteria) For combination panels and multiple models, the key questions are:

Grouping typeKey question for panels and multiple modelsWhat the 2026 checklists require
FamilySame product owner (one or more manufacturing sites), same risk class, same proprietary or brand name, same intended purpose, and the same or very similar physical design, construction and manufacturing process; does every difference between models fall within the permissible variants (section 5.3.1)?The “Permissible variants” column must reflect each item’s actual variants.
IVD Test KitReagents and articles from one product owner, sold under one kit name and used together for one intended purpose; it defines what is inside one kit. A Test Kit application does not cover an analyser used with the kit (section 5.5.2).No dedicated field; separately sold panels do not become one kit through this route.
System / Family of systemsAre the components labelled to be used together for one purpose? The criteria give the example of an IVD System made up of test kits and an analyser designed for use with them (section 5.2).The device description field takes the intended use of the main device.
IVD ClusterSame manufacturer, all Class 1 or 2, the same methodology, and all in the same cluster category? A Cluster may include an analyser designed for use with its reagents (section 5.6).Copy the category name from the closed list; every item must be in the same category.

A rapid test cassette does not become a System because it contains several strips, and several tests do not become a Cluster because they are all respiratory. Respiratory panels are often limited first by risk class: if any one of them is Class 3 or 4 under the Thai rules, IVD Cluster is not available, and the options are a Family or separate applications. Cluster arrangements have changed in other markets (for example Singapore), while Thailand’s 2026 checklists still include IVD Cluster; one market’s position cannot be applied to the other.

Removed targets, specimens and users: map each difference to evidence

The permissible variants table lists specific variable features. For IVDs, Annex 3 lists only a few: different assembly formats for rapid tests (cassette, midstream, strip), different combinations of testing configurations for urinalysis strips, and concentration for antibiotic tests (IVD). A change in the combination of targets is listed only for urinalysis strips; reducing another multiplex panel from seven targets to five is not among the listed variants and cannot be inferred from them. The checklist also notes that a test may have more than one indication or result interpretation, and that study results may need to cover each, as appropriate for the test. (Source: Full-CSDT checklist, performance evaluation section)

Difference between modelsCheck firstSupport usually needed
Targets removed or addedWhether the intended use and result interpretation change; whether each target’s performance still holds in that combination.A statement of which configurations existing performance data cover; additional data for any configuration not covered.
Different specimen typesWhether collection or pre-processing is new or changed.Assessment of equivalence or suitability of specimen types (one of the studies listed in the checklist).
Professional version becomes self-testUsers, procedure and instructions for reading results.User group consistent with the intended use, Thai label and IFU, red warnings, usability test report.
Different appearance or assembly formatCassette, midstream and strip formats of a rapid test are listed variants in Annex 3; other format differences need checking item by item.Description of the variant and the corresponding entry in the criteria.
Different pack sizesWhether only the quantity or packaging form changes.Pack size stated in the item’s additional description; confirmation that components and performance claims are unchanged.

Professional and self-test versions need particular care. The checklist requires the user group (Home use or Professional use) to follow only the intended use shown on the label or IFU. Home-use products need a Thai label and Thai IFU complying with the relevant notifications, self-tests must show warnings in red on the label, and a usability test report is required. Where a test is for both home and professional use and the specimen is not fingertip blood, a nasal swab, urine, stool or saliva, or the collection method must be performed by healthcare personnel, the labelling must state which collection may be performed only by healthcare personnel and which by lay users, for example fingertip blood only for lay users. (Source: Full-CSDT checklist, application form item 8, IFU section on p. 9, and the labelling and performance sections) Even if the two versions share analytical performance reports, state what is shared and what differs; whether they can go into one application should be confirmed with Thai FDA on the basis of the full product file.

Illustrative example: splitting four respiratory antigen panels

The following is a hypothetical scenario that illustrates the method only; it is not a classification or grouping conclusion for any product. A manufacturer plans to sell four antigen panels in Thailand: A has three targets, B and C each drop one of them, and D keeps only the two non-COVID targets. All four share a brand, each has its own catalogue number, and each has a professional and a self-test version, giving eight catalogue numbers.

StepWhat to do for the eight catalogue numbersOutcome that may shape the application boundary
1. Risk classClassify each one under the Thai rules.If any one is Class 3 or 4, IVD Cluster is ruled out.
2. Family checkCompare targets, specimens and intended use column by column against the permissible variants table.If removing targets is not a permissible variant, A–D are hard to combine as a Family.
3. UsersCheck labels, IFUs, warnings and usability evidence separately for professional and self-test versions.The maturity of the self-test file may decide whether it is filed together with the professional versions.
4. Evidence coverageMark the performance data each catalogue number can share and the data unique to it.Catalogue numbers with insufficient evidence can be deferred and filed later once the evidence is complete.
5. Questions to confirmTurn anything the rules do not settle into specific questions.Confirm with Thai FDA, attaching IFUs, composition diagrams and the comparison table.

In this scenario, the number of applications could range from one covering several catalogue numbers to several split by panel or by user. Estimate the number of applications and fees once these points are settled, rather than giving a fixed answer on the day the product catalogue arrives.

Adding models to an approved product is a separate change decision

The first page of the checklist states that once an application has been approved, adding product items or documents requires a later amendment application. (Source: Full-CSDT checklist, p. 1) That does not mean every new model can be added by amendment. Compare the new model with the approved scope, record differences in intended use, targets, specimens and configuration, and then apply the current change rules; if the new model falls outside the original grouping conditions, a new application needs to be considered. For the 2026 change categories and fees, see our guide to Thai medical device amendments.

What to prepare before the grouping is confirmed

MediPass suggests preparing a model matrix that can be checked item by item, with each product’s proposed label and IFU, diagrams of modules and components, the basis for risk classification, the relationship between manufacturer and product owner, and a table of what each performance report covers. Where documents are to be shared, give the reason; where applications are to be split, align the boundary with the launch plan.

If the products are already approved elsewhere, add a table comparing the approved scope with the catalogue numbers to be sold in Thailand. Grouping decisions in other markets help explain the product structure, but acceptance in Thailand still depends on Thai rules. When asking the regulator, narrow the question to specific configurations, for example “can the B and C target combinations be grouped with A in the proposed Family?”, with reasons and evidence, rather than asking in general whether one certificate can cover several models.

Frequently asked questions

Do different pack sizes always need separate applications?
Not necessarily. The checklist recommends giving the pack size in each item’s additional description so that items can be told apart. The key is to confirm that only the quantity or packaging form changes, not the components, intended use or performance claims.

Can tests for the same target but different specimen types be combined?
Check the conditions of the proposed grouping and provide supporting evidence for each specimen type; the checklist lists assessment of equivalence or suitability of specimen types among the studies that can be submitted. A shared target alone does not settle the question.

Is IVD Cluster still available in Thailand?
Yes. Both the May 2026 Full-CSDT and Abridged checklists keep the IVD Cluster requirements: choose the category from the closed list, with every item in the same category. The items must come from the same manufacturer, be Class 1 or 2 and use the same methodology, and changes in other markets cannot be applied directly.

Is it simpler to register fewer models now and add the rest later?
Not necessarily. Adding items after approval requires an amendment application, and new models must still fit the original group; if they do not, a separate application is needed. Weigh the first launch plan, the maturity of the evidence and the feasibility of later changes together.

Official references

  1. Thai FDA Medical Device Control Division, Checklist แนวทางการพิจารณาเอกสารคำขอขึ้นทะเบียนเครื่องมือแพทย์ (Full-CSDT) ประเภท IVD Class 2-4 (review checklist for full CSDT registration applications, IVD Class 2–4), IVD_MDCD_CL_FU Rev.01, p. 1: adding items after approval; pp. 2–3: application form items 8–10 and Items rows 1–6; labelling, IFU and performance evaluation sections, 25 May 2026 (B.E. 2569), cms-media.fda.moph.go.th (PDF)
  2. Thai FDA Medical Device Control Division, Checklist แนวทางการพิจารณาเอกสารคำขอขึ้นทะเบียนเครื่องมือแพทย์ (Abridged) ประเภท IVD Class 2-4 (review checklist for abridged registration applications, IVD Class 2–4), IVD_MDCD_CL_AB Rev.1, pp. 2–3: grouping entries, 25 May 2026 (B.E. 2569), cms-media.fda.moph.go.th (PDF)
  3. Thai FDA, หลักเกณฑ์ในการจัดกลุ่มเครื่องมือแพทย์ พ.ศ. 2561 (Medical Device Grouping Criteria), clause 1: six grouping forms; annex sections 5.2, 5.3, 5.5 and 5.6; Annex 3: Family permissible variants (including IVD rapid tests and IVD urinalysis strips); Annex 7: IVD Cluster categories, 26 October 2018 (B.E. 2561), medical.fda.moph.go.th (PDF)

Prepared from official sources verifiable as of 27 May 2026 for manufacturers’ project planning; the risk class, grouping and application scope for a specific product must be confirmed against the full product file and Thai FDA’s view.

Leave a Comment

Your email address will not be published. Required fields are marked *

Chat on WhatsAppWhatsApp 咨询